NASDAQ:RGLS

Regulus Therapeutics Insider Trades

$1.29
-0.11 (-7.86 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.22
Now: $1.29
$1.38
50-Day Range
$1.15
MA: $1.51
$1.96
52-Week Range
$0.42
Now: $1.29
$2.32
Volume1.70 million shs
Average Volume3.04 million shs
Market Capitalization$93.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41

Insider Trades

Regulus Therapeutics (NASDAQ:RGLS) Insider Buying and Selling Activity

Insider Ownership Percentage: 18.24%
Insider Buying (Last 12 Months): $2,727,133.24
Insider Selling (Last 12 Months): $14,991.81

Insider Buying and Selling by Quarter


Regulus Therapeutics (NASDAQ RGLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2021Christopher Ray AkerVPSell828$1.72$1,424.1642,614  
2/16/2021Joseph P HaganCEOSell4,144$1.72$7,127.68485,756  
12/4/2020Paul Edward WalkerMajor ShareholderBuy4,398,602$0.62$2,727,133.24  
8/14/2020Christopher Ray AkerVPSell872$0.61$531.9226,638  
8/14/2020Joseph P HaganCEOSell4,245$0.60$2,547.00222,088  
5/15/2020Christopher Ray AkerVPSell909$0.63$572.6727,510  
5/15/2020Joseph P HaganCEOSell4,426$0.63$2,788.38226,333  
2/18/2020Christopher Ray AkerVPSell888$0.83$737.0428,419  
2/18/2020Joseph P HaganCEOSell4,324$0.83$3,588.92230,759  
1/2/2020Christopher Ray AkerVPSell2,239$0.97$2,171.8329,307  
1/2/2020Joseph P HaganCEOSell8,345$0.97$8,094.65235,083  
11/14/2019Christopher Ray AkerVPSell833$0.64$533.1231,546  
11/14/2019Joseph P HaganCEOSell5,838$0.64$3,736.32243,428  
10/1/2019Christopher Ray AkerVPSell2,346$0.68$1,595.2832,379  
10/1/2019Joseph P HaganCEOSell8,743$0.68$5,945.24249,266  
8/15/2019Christopher Ray AkerVPSell899$0.55$494.45  
8/15/2019Joseph P HaganInsiderSell4,375$0.55$2,406.25  
7/1/2019Christopher Ray AkerVPSell2,225$1.31$2,914.7535,624  
7/1/2019Daniel R ChevallardCFOSell2,669$1.31$3,496.3977,870  
7/1/2019Joseph P HaganInsiderSell5,783$1.31$7,575.73262,384  
5/16/2019Joseph P HaganInsiderSell39,352$1.22$48,009.44307,519  
5/15/2019Christopher Ray AkerVPSell6,950$1.41$9,799.5066,259  
5/15/2019Daniel R ChevallardCFOSell10,000$1.41$14,100.0090,539  
5/7/2019Joseph P HaganCEOBuy33,194$1.08$35,849.5264,542  
5/7/2019Pascale WitzDirectorBuy29,630$1.08$32,000.4037,849  
5/7/2019Peter J BarrisMajor ShareholderBuy1,136,704$1.08$1,227,640.32  
4/1/2019Christopher Ray AkerVPSell2,710$0.98$2,655.806,287  
4/1/2019Daniel R ChevallardCFOSell3,253$0.98$3,187.949,372  
4/1/2019Joseph P HaganCEOSell5,842$0.98$5,725.1631,348  
12/28/2018Stelios PapadopoulosDirectorBuy50,000$1.09$54,500.00835,073  
12/27/2018Stelios PapadopoulosDirectorBuy116,401$0.97$112,908.97758,672  
11/16/2018Kathryn J CollierDirectorBuy7,100$1.41$10,011.0027,596  
7/25/2017Daniel R ChevallardCFOBuy54,945$0.91$49,999.9559,415  
7/25/2017Joseph P HaganInsiderBuy219,780$0.91$199,999.80241,297  
7/25/2017William H RastetterDirectorBuy274,725$0.91$249,999.75  
3/22/2017Stelios PapadopoulosDirectorBuy500,000$1.22$610,000.00400,677  
3/7/2017William H RastetterDirectorBuy250,000$1.15$287,500.00  
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.0010,000  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.004,896,716  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.8950,000  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.8550,000  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.0050,000  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00  
(Data available from 1/1/2013 forward)
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.